SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group (DJT) is trending amid discussions about its financial performance and the ongoing release of Epstein-related documents. The community is expressing concerns about the company's future and the potential impact of these external factors, including political opinions and a mix of reactions, from staunch support to harsh criticism. Speculation is also circulating regarding potential market manipulation and the stock's long-term viability.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as it dips below $100K, sparking discussions about potential support levels and the possibility of a larger correction. The crypto community is debating whether this is a buying opportunity or the start of a bear market, with some pointing to ETF flows and long-term holder behavior.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending amid a recent announcement of a $2.35 billion senior secured notes offering, leading to community debate around the company's debt strategy and its potential impact on growth. Community members are weighing the implications of this financial move against the backdrop of the AI sector's volatility, discussing whether this is a buying opportunity or a sign of deeper issues. Despite differing opinions, the company's existing contracts and long-term potential in the AI data center space remain central talking points.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Anavex Life Sciences Corp

AVXL is trending as investors await a decision on its Alzheimer's treatment from the European Medicines Agency, with a hearing completed recently. Community discussions range from potential approval and short squeeze scenarios to concerns about data integrity and potential insider trading, fueled by commentary from controversial figures. The stock exhibits high volatility amidst speculation about the drug's prospects and impact on the broader Alzheimer's treatment landscape.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

RCAT is trending due to lowered FY2025 revenue guidance, sparking concerns about short-term performance, while the community debates management and potential reverse splits. Despite the reduced outlook, long-term growth prospects related to defense and maritime contracts, along with analyst 'Strong Buy' ratings, are still being discussed, with some viewing the dip as a buying opportunity.

TSS, Inc. engages in the provision of comprehensive services for the planning, design, development and maintenance of mission-critical facilities and information infrastructure as well as integration services. It operates through the Facilities and Systems Integration Services business segments. The Facilities segment consists of the design, project management, and maintenance of data center and mission-critical business operations. The Systems Integration segment integrates information technology equipment for original equipment manufacturer vendors and customers to be used inside data center environments, including modular data centers. The company was founded by Gerard J. Gallagher on December 20, 2004 and is headquartered in Round Rock, TX.

TSS Inc

TSSI is trending downwards as investors express concerns about decreased revenue and profit, despite overall year-to-date growth. The community is debating whether recent facility upgrades and reliance on Dell will support future expansion and profitability, especially given lower numbers in recent earnings. Contrarian investors are hopeful for a bounce, citing a recent capital raise, while others express disappointment and question the company's communication strategy.

Cidara Therapeutics, Inc. engages in developing targeted immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. Its platform, Cloudbreak, enables development of novel drug-Fc conjugates (DFCs) that inhibit specific disease targets while simultaneously engaging the immune system. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Cidara Therapeutics Inc

Cidara Therapeutics is trending amid speculation of a potential acquisition, with community members discussing rumors of a bidding war involving major pharmaceutical companies. The positive Phase 2 clinical data for their influenza candidate CD388 and a recent $339M BARDA award have increased optimism around the stock. Investors are closely watching for further developments, including potential price target updates and signals of a buyout.

Applied Materials, Inc. provides manufacturing equipment, services and software to the semiconductor, display and related industries. It operates through the following segments: Semiconductor Systems, Applied Global Services, and Display. The Semiconductor Systems segment includes semiconductor capital equipment for etch, rapid thermal processing, deposition, chemical mechanical planarization, metrology and inspection, wafer packaging, and ion implantation. The Applied Global Services segment provides solutions to optimize equipment, performance, and productivity. The Display segment offers products for manufacturing liquid crystal displays, organic light-emitting diodes, equipment upgrades, and other display technologies for TVs, monitors, laptops, personal computers, smart phones, and other consumer-oriented devices. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.

Applied Materials Inc.

Applied Materials is trending due to a mixed earnings report and weaker-than-expected guidance, sparking debate about its future growth prospects, particularly in China. The community is focused on whether the recent drop presents a buying opportunity or if it signals deeper challenges for the semiconductor equipment supplier. Discussions include the impact of potential tariffs and competition from other companies in the sector.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Kura Oncology Inc

Kura Oncology is trending due to recent FDA approval of their leukemia drug, KOMZIFTI, ahead of schedule, leading to community excitement around its potential market impact and improved safety profile compared to competitors. The community is actively discussing the implications of the approval, including potential milestone payments and the drug's advantages in dosing and safety, while also considering its competitive positioning against similar treatments. Despite some volatility and profit-taking, the approval is seen as a positive catalyst for the company's growth and potential acquisition.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as investors discuss its potential for government backing and key developments from the latest earnings report. The community is focused on the CEO's trip to Washington D.C. and anticipation surrounding NOAA approval, with some highlighting the company's role in securing defense minerals amid geopolitical tensions.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Shares surged 141% to $6.41, marking their highest level since February 2024, after Minerva secured up to $200 million in financing led by top healthcare investors.</li><li>The FDA cleared the design for a confirmatory Phase 3 trial of roluperidone, a potential treatment for the negative symptoms of schizophrenia.</li><li>Retail traders on Stocktwits turned “extremely bullish,” citing the new funding and FDA alignment as signs of confidence in an eventual approval.</li></ul>Minerva Neurosciences' stock jumped to a nearly two-year high on Tuesday after the biotech firm announced a new financing deal that could bring in up to $200 million and outlined a clear regulatory path with the U.S. FDA for its lead schizophrenia drug, roluperidone.The company’s shares&nbsp;soared 141% to $6.41 on Tuesday, hitting their highest level since February 2024, before slipping 6.4% in after-hours trading.<h2 class="st-heading-2">Funding For Phase 3 Trial And NDA Resubmission</h2>Minerva said it raised $80 million upfront through a private financing round backed by leading healthcare investors, including Vivo Capital, Janus Henderson Investors, and Federated Hermes Kaufmann Funds.&nbsp;The deal could bring in as much as $200 million in total, with another $80 million tied to the exercise of Tranche A warrants and an additional $40 million linked to future clinical milestones under Tranche B warrants. Each preferred share was priced at $1,000, convertible into common stock at $2.11 pending shareholder approval.The firm said the investment would fully fund its planned confirmatory Phase 3 study of roluperidone, and NDA resubmission to the FDA. It will also be used to make preparations for a potential U.S. commercial launch, should the product gain approval.<h2 class="st-heading-2">Strengthening The Team</h2>Under the agreement, Minerva will increase the number of its directors to include up to three new members with significant experience in schizophrenia and drug development. The company also plans to establish a Scientific Advisory Board to help guide the Phase 3 study.“We will now refocus all of our efforts on the successful execution of the confirmatory trial with the objective of demonstrating that roluperidone can effectively treat patients with impairing negative symptoms,” CEO Remy Luthringer said in a statement.<h2 class="st-heading-2">FDA Agrees On Clear Trial Design</h2>The FDA has agreed on the design of the confirmatory Phase 3 study, which will test roluperidone 64 mg as a standalone treatment in patients with schizophrenia who suffer from negative symptoms such as lack of motivation, social withdrawal, and diminished emotional expression. The main goal of the trial will be to measure improvements in the PANSS Marder Negative Symptoms Factor Score after 12 weeks.The FDA has also asked Minerva to observe patients for up to 52 weeks to monitor relapse rates, helping to build evidence for roluperidone as a monotherapy. The company expects around 25%–30% of trial participants to be enrolled from U.S. sites.<h2 class="st-heading-2">Stocktwits Traders Eye FDA Milestone Upside</h2>On Stocktwits, retail sentiment for Minerva was ‘extremely bullish’ amid a 102,300% surge in 24-hour message volume.One user said they expected Minerva’s stock to climb sharply if it breaks past the $7 level, while another pointed to the company’s $200 million financing as a sign of confidence, suggesting that such investment likely reflects optimism around eventual FDA approval.<stembedurl>https://stocktwits.com/24cmKarMadhfromPrishtina/message/633140308</stembedurl><stembedurl>https://stocktwits.com/Myway1000/message/633126607</stembedurl><a href="https://stocktwits.com/symbol/NERV">Minerva’s stock</a> has nearly tripled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Minerva Neurosciences logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Minerva Neurosciences Stock Hits Near 2-Year High On FDA Pathway, $200M Boost — Retail Sees FDA Catalyst

Shares surged 141% to $6.41, marking their highest level since February 2024, after Minerva secured up to $200 million in financing led by top healthcare investors.

Equity

Minerva Neurosciences, Inc. (NASDAQ:NERV) Sees Significant Decline in Short Interest

Minerva Neurosciences, Inc. (NASDAQ:NERV  Get Free Report) was the recipient of a large decrease in short interest in March. As of March 15th, there was short interest totalling 38,300 shares...

Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

BURLINGTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...

Minerva Neurosciences (NASDAQ:NERV) Cut to "Sell" at StockNews.com

StockNews.com downgraded shares of Minerva Neurosciences (NASDAQ:NERV  Free Report) from a hold rating to a sell rating in a research note published on Friday. Minerva Neurosciences Trading...

Minerva Neurosciences: Q4 Earnings Insights

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates

BURLINGTON, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...

Minerva Neurosciences (NASDAQ:NERV) Raised to Hold at StockNews.com

StockNews.com upgraded shares of Minerva Neurosciences (NASDAQ:NERV  Free Report) from a sell rating to a hold rating in a research note released on Monday. Minerva Neurosciences Stock...

Minerva Neurosciences (NASDAQ:NERV) Cut to Sell at StockNews.com

StockNews.com lowered shares of Minerva Neurosciences (NASDAQ:NERV  Free Report) from a hold rating to a sell rating in a research note issued to investors on Friday. Minerva Neurosciences...

Minerva Neurosciences (NASDAQ:NERV) Stock Rating Lowered by StockNews.com

Minerva Neurosciences (NASDAQ:NERV  Get Free Report) was downgraded by equities researchers at StockNews.com from a hold rating to a sell rating in a research...

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

Minerva Neurosciences Inc

$IONQ

$RGTI

$QBTS

$QUBT

Are you buying the dip on any of these quantum stocks? 
 
If no, drop a comment.

Current Price	$3.85
Prev Close	$4.00
Open	$3.88
Dividend Yield	0.00%
50-Day Moving Average	$2.96
Beta	1.14
Avg. Volume	8.15M
PE Ratio	-2.16

52-Week High	$12.46
52-Week Low	$1.15
Market Capitalization	$27.97M
EPS (Annual)	$0.19
Price to Book	-0.81
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

NERV
Minerva Neurosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NERV News

NERVMinerva Neurosciences Inc